Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Magungunan da aka Gabatar da Farko a cikin Maganin Ciwon Nono Yana Ba da Fata

Written by edita

A duniya baki daya, R&D akan kansar nono a kowane nau'insa yana ci gaba da girma cikin sauri a cikin shekaru da yawa da suka gabata kuma zai ci gaba a cikin shekaru masu zuwa. Cutar sankarar mama ita ce ta biyu mafi yawan cutar kansa a duniya kuma ita ce cutar kansa mafi yawan mata a duniya.

Mutum mai karɓar haɓakar haɓakar haɓakar ɗan adam 2-tabbatacce (HER2+) ciwon nono ya ƙunshi kusan 20% na cutar kansar nono kuma a tarihi yana da alaƙa da rashin fahimta mara kyau idan babu ingantattun jiyya. Sanin cewa gabatar da hanyoyin kwantar da hankali na HER2 a baya cikin dabarun kula da cututtuka na iya inganta rayuwa mara cuta (DFS) ya haifar da babbar kasuwa don hanyoyin kwantar da hankali na HER2. A yau, masu ciwon daji na HER2+ suna rayuwa tsawon lokaci tare da cutar su, godiya ga kafa tsarin kula da cututtuka ta hanyar amfani da tsarin. Dangane da Binciken Kasuwancin Stats, ana hasashen kasuwar HER2+ za ta yi girma zuwa $12.1B nan da 2030, a Haɗin Ci gaban Shekara-shekara (CAGR) na 1.5%. Wani rahoto daga Mordor Intelligence ya kara da cewa ana sa ran kasuwar maganin kansar nono za ta yi girma a CAGR na 8.3% a cikin lokacin hasashen, 2022-2027. 

Rahoton ya ce: “Sakamakon barkewar COVID-19, kasuwar ta fuskanci koma baya sakamakon jinkirin gano cutar, karancin magunguna, da kuma rashin kwararrun likitocin kiwon lafiya. Misali, bisa ga wata labarin da aka buga a cikin hanyar sadarwa ta JAMA a watan Agusta 2020, an sami raguwa sosai a cikin cututtukan cututtukan daji na nono (kimanin 51.8%) a cikin Amurka daga Maris 1, 2020, zuwa Afrilu 18, 2020. Don haka , jinkirin gano cutar kansar nono ya yi tasiri ga maganin irin wannan. Don haka, cutar ta COVID-19 ta yi mummunar tasiri ga kasuwar maganin cutar kansar nono a matakin farko. Koyaya, ana sa ran kasuwar za ta sami karbuwa a cikin shekaru masu zuwa yayin da ake dawo da jiyya a duk duniya." Ayyukan fasahar kere-kere da kamfanonin harhada magunguna a kasuwanni a wannan makon sun hada da Oncolytics Biotech® Inc., Clovis Oncology, Inc., Belite Bio Inc., Endo International plc, Pfizer Inc.

Binciken Kasuwar Stats ya ci gaba da cewa: “Bugu da ƙari, manyan abubuwan da ke haifar da haɓakar kasuwar su ne yawaitar yawaitar cutar kansar nono a duk duniya, haɓaka saka hannun jari a cikin bincike da haɓakawa, da ci gaba a ilimin halittar kansa da ilimin harhada magunguna waɗanda ke haɓaka haɓakar magunguna. Yawan yawaitar cutar kansar nono a duk duniya shine babban abin da ke haifar da ci gaban kasuwa. A cikin Arewacin Amurka, ana tsammanin Amurka za ta mamaye kasuwa gaba ɗaya a duk lokacin hasashen. Manyan abubuwan da ke kara habaka kasuwannin su ne yadda cutar kansar nono ke karuwa a kasar da kuma kara wayar da kan jama’a game da cutar kansar nono da kuma karuwar kaddamar da kayayyaki.”

Oncolytics Biotech® da SOLTI sun Gabatar da Sabbin Bayanan Halittun Halitta na Clinical Yana Nuna Ƙimar Pelareorep don Inganta Ciwon Ciwon Ciwon Ciwon Nono a Taron Ciwon Kan Nono na ESMO - Oncolytics Biotech® da SOLTI-Innovative Cancer Research a yau sun sanar da sabon bayanan biomarker na asibiti wanda ke nuna alamun pelaretherarep tare da immunorep. hanawa wuraren bincike, da yuwuwar inganta hangen nesa ga marasa lafiya da HR +/HER2- ciwon nono. Bayanan, waɗanda aka nuna a cikin gabatarwar fosta a taron 2022 European Society for Medical Oncology (ESMO) Taron Ciwon Kan Nono, sun fito ne daga ƙungiyoyin 1 da 2 na AWARE-1 ​​na binciken taga-na-dama a cikin marasa lafiya na ciwon nono na farko.

Marasa lafiya a cikin ƙungiyoyi biyu na AWARE-1 ​​na farko an bi da su tare da pelareorep da aromatase inhibitor letrozole ba tare da (cohort 1), ko kuma tare da (2) mai hanawa na PD-L1 mai hanawa atezolizumab kamar kwanaki 21 kafin aikin tiyata na ciwace-ciwacen su. Ƙungiyoyin 1 da 2 na AWARE-1 ​​sun yi rajista na musamman da marasa lafiya tare da HR +/HER2-cutar, nau'in ciwon nono wanda Oncolytics ke niyyar yin nazari a cikin binciken rajista na gaba. Sakamakon da aka ruwaito a baya ya nuna AWARE-1 ​​ya sadu da ƙarshen fassararsa na farko, tare da ƙungiyar 2 ta cimma ƙayyadaddun ƙayyadaddun nasarar da aka ƙayyade don haɓakar jiyya a cikin CelTIL maki (haɗi zuwa PR). Makin CelTIL ma'auni ne don kumburin ƙari da salon salula kuma yana da alaƙa da ingantattun sakamakon asibiti a cikin masu cutar kansar nono.

"Sabuwar bayanai daga AWARE-1 ​​sun kara nuna yiwuwar pelareorep don inganta sakamakon asibiti a cikin marasa lafiya da ciwon nono ta hanyar ikonsa na kunna kwayoyin T da kuma sake gyara ƙwayar ƙwayar ƙwayar cuta," in ji Thomas Heineman, MD, Ph.D., Babban Jami'in Lafiya na Oncolytics. . "Musamman, jiyya na pelareorep ya karu alamun mutuwar ƙwayar ƙwayar cuta kuma, watakila ma mafi ban sha'awa, 100% na marasa lafiya da aka yi wa maganin pelareorep suna da haɗarin sake dawowa (ROR-S) idan aka kwatanta da 55% a asali. Tare, waɗannan sabbin sakamakon AWARE-1 ​​sun ƙara tabbatar da ikon pelareorep na kai hari ga ciwace-ciwace ta hanyoyi da yawa.

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...